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Antimicrobial Susceptibility of
Brucella melitensis
Isolates from Blood Samples
Aim: Brucellosis is a worldwide zoonotic disease that remains an important public health problem in rural
Turkey. The aim of the present study was to identify Brucella species and biotypes, and to assess the
antimicrobial susceptibility of isolates from blood samples.
Materials and Methods: The study included 46 Brucella isolates from the K›r›kkale region of central
Anatolia. The identification and biotyping of the isolates were based on conventional methods. The minimal
inhibitory concentration (MIC) values of tetracycline, rifampin, streptomycin, ciprofloxacin, and azithromycin
were determined using the E test method.
Results: All isolates were identified as B. melitensis (45 isolates, biotype-3) and were sensitive to tetracycline,
streptomycin, ciprofloxacin, and azithromycin. In all, 2 isolates showed intermediate sensitivity to rifampin,
whereas the others were sensitive. MIC90 values of tetracycline, streptomycin, rifampin, ciprofloxacin, and
azithromycin were 0.25 mg/l, 0.50 mg/l, 1.0 mg/l, 0.25 mg/l, and 1.0 mg/l, respectively.
Conclusions: In recent years there has been tremendous interest in the identification of Brucella strains and
their antimicrobial susceptibility. According to antimicrobial susceptibility test results, none of the isolates in
the K›r›kkale region of Turkey were resistant to the currently recommended antibiotics. The present study’s
findings were discussed along with a brief review of similar studies from Turkey.
Key Words: Brucellosis, tetracycline, streptomycin, rifampin, ciprofloxacin, azithromycin

Kan Örneklerinden Elde Edilen
Brucella melitensis Suﬂlar›n›n
Antimikrobiyal Duyarl›l›k Sonuçlar›
Amaç: Bruselloz tüm dünyada yayg›n olarak görülen ve ülkemizde k›rsal alanlar baﬂta olmak üzere önemli bir
sa¤l›k sorunu oluﬂturan zoonotik bir hastal›kt›r. Bu çal›ﬂmada, kan örneklerinden izole edilen Brucella cinsi
bakterilerde tür/biyotip tayini yap›lmas› ve bu suﬂlar›n antimikrobiyal duyarl›l›klar›n›n belirlenmesi
amaçlanm›ﬂt›r.
Yöntem ve Gereç: Çal›ﬂmaya K›r›kkale ilinde kan kültürlerinden izole edilmiﬂ 46 Brucella suﬂu al›nm›ﬂt›r.
‹zolatlar›n identifikasyon ve tür/biyotip tayininde konvansiyonel yöntemler kullan›lm›ﬂt›r. Tetrasiklin,
streptomisin, rifampisin, siprofloksasin ve azitromisin için minimal inhibitör konsantrasyon (M‹K) de¤erlerinin
belirlenmesinde E-test yöntemi kullan›lm›ﬂt›r.
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Bulgular: Tüm izolatlar B. melitensis (45’i biyotip-3) olarak belirlenmiﬂtir. Antibiyotik duyarl›l›k sonuçlar›na
bak›ld›¤›nda, izolatlar›n tümü tetrasiklin, streptomisin, siprofloksasin ve azitromisin’e duyarl› bulunmuﬂtur.
K›rkdört suﬂ rifampine duyarl›, iki suﬂ ise orta duyarl› olarak saptanm›ﬂt›r. Tetrasiklin, streptomisin, rifampin,
siprofloksasin ve azitromisin için M‹K90 de¤erleri s›ras›yla 0,25 mg/l, 0,50 mg/l, 1,0 mg/l, 0,25 mg/l ve 1,0
mg/l olarak de¤erlendirilmiﬂtir.
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Sonuç: Son y›llarda, Brucella suﬂlar›n›n identifikasyon ve antimikrobiyal duyarl›l›klar›n›n belirlenmesi üzerine
büyük bir ilgi art›ﬂ› vard›r. Antibiyotik duyarl›l›k sonuçlar› Brucella suﬂlar›nda kullan›lmakta olan konvansiyonel
ilaçlara karﬂ› in vitro direnç olmad›¤›n› göstermektedir. Bu çal›ﬂmadan elde edilen bulgular, Türkiye’de bu
konuda yap›lan benzer çal›ﬂmalar ve dünya verileri eﬂli¤inde gözden geçirilmiﬂtir.
Anahtar Sözcükler: Bruselloz, tetrasiklin, streptomisin, rifampin, siprofloksasin, azitromisin
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Introduction
Human brucellosis is a multisystemic disease
characterized by a prolonged clinical course and relapses.
Severe complications involving musculoskeletal,
neurological, genitourinary, and cardiovascular systems
may be encountered during the course of the disease (13). Brucellae are intracellular microorganisms that can
survive inside macrophages by counteracting a number of
host defense mechanisms. The prevention of relapses and
serious sequelae may be accomplished through the
combined use of antimicrobials that have the ability to
penetrate into intracellular compartments and retain their
efficacy, even in an acidic environment (4-6).
Tetracycline and its congeners are the most effective
antibiotics for brucellosis, and constitute the basic
component of any combination regimen. The
recommended treatment scheme for brucellosis is the
combination of doxycycline and either streptomycin or
rifampin for 6 weeks. Nevertheless, some cases with
severe complications may require more than 2
antimicrobial drugs and a longer treatment course
(1,6,7).
The purpose of the present study was to identify
Brucella species and biotypes in blood samples obtained
from brucellosis patients from the Kırıkkale region of
central Anatolia. In addition, we aimed to determine their
in vitro susceptibility to 3 basic (tetracycline, rifampin,
streptomycin) and 2 alternative (ciprofloxacin and
azithromycin) antibiotics.

Materials and Methods
Methods

Brucellae were isolated from patients with brucellosis
that were diagnosed at the Infectious Diseases and Clinical
Microbiology Department of Kırıkkale University Faculty
of Medicine between October 2002 and September
2004. In total, 46 isolates were included the study.
Brucella isolates were obtained from blood using the
BACTEC 9050 (Becton Dickinson, Sparks, Maryland,
USA) automated blood culture system. Confirmation,
identification, and antimicrobial susceptibility testing of all
the strains took place at the Refik Saydam National
Institute of Hygiene, Department of Communicable
Diseases Research.
258
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The identification methods, Brucella typing
procedures, and antimicrobial susceptibility testing used
in this study have been described in detail previously
(8,9). Briefly, the suspected colonies on serum dextrose
agar and Brucella agar supplemented with 5% horse
serum were evaluated based on Gram stain, growth
characteristics, oxidase, and catalase tests. Subsequently,
nitrate reduction, motility, requirement of X and V
factors, biochemical reactions, including indole, VogesProskauer test, citrate, and gelatin hydrolysis tests, were
performed. Finally, slide agglutination was tested with
anti-Brucella polyclonal serum. For species and biotype
identification; the requirement of CO2 for growth,
production of urease and H2S, dye sensitivity (thionine
and basic fuchsin), susceptibility to Tbilisi phage, and
agglutination with monospecific antisera for A and M
antigens were utilized. The strains were stored in skim
milk at –80 °C and subcultured twice before beginning
the study.
MIC values of tetracycline, rifampin, streptomycin,
ciprofloxacin, and azithromycin were determined using
the E test (AB Biodisk). Antimicrobial susceptibility
testing was performed by inoculating the bacterial
suspension (adjusted to 0.5 McFarland) onto MuellerHinton agar plates supplemented with 5% sheep blood
and then applying E test strips. MIC was evaluated after
48 h of incubation. B. abortus 19, B. melitensis 16M, and
B. suis 1330 were used as reference strains. Since MIC
breakpoints have not yet been established for Brucella
spp., MIC values were interpreted according to Clinical
Laboratory Standards Institute (CLSI) guidelines
[formerly, the National Committee for Clinical Laboratory
Standards (NCCLS)] for slow-growing bacteria
(Haemophilus spp.) (10).

Results
All 46 isolates sent to the reference laboratory were
identified as B. melitensis. All but one (biotype-1) of the
isolates (biotype-3) agglutinated with both anti-A and
anti-M monospecific sera.
MIC50 and MIC90 values of the relevant antibiotics are
shown in Table 1. All isolates were sensitive to
tetracycline,
streptomycin,
ciprofloxacin,
and
azithromycin. In all, 44 isolates were sensitive and 2
isolates showed intermediate sensitivity to rifampin based
on the criteria for slow-growing bacteria.
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Table 1. The antimicrobial susceptibility of 46 B. melitensis isolates from blood samples.
Antibiotics

MIC Range (mg/l)

MIC50 (mg/l)

MIC90 (mg/l)

Tetracycline

0.023-0.38

0.125

0.25

Streptomycin

0.125-0.50

0.25

0.50

Rifampin

0.125-1.5

0.50

1.0

Ciprofloxacin

0.047-0.50

0.125

0.25

Azithromycin

0.064-1.5

0.75

1.0

Conclusions
In recent years a vast quantity of data regarding the
identification and in vitro antimicrobial susceptibility of
Brucella strains has been accumulated; publications from
Turkey (6, 9, 11-14), as well as the present study, are
summarized in Table 2. In Turkey, B. melitensis is the
most common species and the majority of isolates are
biotype-3. B. abortus was identified as a causative agent
in only 1 study (5 isolates) (12). Future molecular
biological studies, rather than the conventional methods
previously utilized, will lead to the exact genetic
classification of Brucella spp.

Routine in vitro antimicrobial susceptibility testing of
Brucella spp. is not generally recommended (2,12). Such
testing carries the risk of contagiousness among
laboratory personnel and requires biological safety level 3
precautions (2,15). Moreover, in vitro antimicrobial
susceptibility does not always predict clinical efficacy.
Treatment failure in brucellosis is related to such factors
as inappropriate dose, short-term administration,
insufficient intracellular penetration of the drug, and poor
patient compliance, rather than drug resistance
(7,15,16); however, antimicrobial susceptibility testing
may be recommended in cases of life-threatening organ

Table 2. Summary of Brucella antimicrobial susceptibility test results of Turkish studies.
Researcher

Akova et al.

Bodur et al.

Baykam et al.

Kose et al.

Sengoz et al.

Yamazhan et al.

Ayaslioglu et al.

Ankara

Ankara

Ankara

‹zmir

‹stanbul

‹zmir

K›r›kkale

Isolate #

43

41

42

11

43

44

46

B. melitensis

43

41

37

11

43

44

46

(biotype 3)

(ND)

(39)

(29)

(10)

(ND)

(ND)

(45)

B. abortus

0

0

5

0

0

0

0

Microdilution

E test

E test

E test

E test

Agar dilution

E test

DOX

< 0.125

0.064

0.064

0.047

0.090

0.50

0.25*

STR

2.0

Region

MIC90(mg/l)

Method

0.75

SXT

0.38

1.5

1.0

CRO

0.38

0.50

0.50

RIF

2.0

0.75

1.0

0.75

1.0

CIP

2.0

0.25

0.19

0.25

0.38

AZM

1.0

0.50

1.0
2.0

0.25

32.0

1.0

DOX: doxycycline; STR: streptomycin; SXT: trimethoprim/sulfamethoxazole; CRO: ceftriaxone; RIF: rifampin; CIP: ciprofloxacin; AZM: azithromycin.
ND: not determined.
*E strip for tetracycline was used.
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involvement (i.e. brucella endocarditis and meningitis)
and in the event of treatment failure and relapse (16).
An additional problem with such testing is the lack of
standardization. In vitro efficacy of antibiotics against
Brucella spp. has usually been based on the determination
of MIC values by micro broth dilution, agar dilution, and
E test methods. The disc diffusion method has not been
recommended (4). Most studies from Turkey utilized the
E test method and usually declared concordant results
(9,11-13). The E test is said to be more reliable,
reproducible, and practical, as well as less labor-intensive
and time-consuming than other methods (9,17). A
previous study that compared the E test to the
microdilution test reported no significant difference
between MIC end-points (17); however, Akova et al. (6)
detected somewhat higher MIC values with the
microdilution method than with the E test method and
Yamazhan et al. (14), using the agar dilution method,
noted even higher MIC values for all the tested
antimicrobials. These discordant findings may be
attributed to either regional differences in the
susceptibility of Brucella strains or to the different
methodologies used to assess the MIC values.
Tetracycline and its derivatives are among the most
effective drugs against brucellosis (1,7). Despite their
widespread use in eradicating Brucella infections, there is
no problem associated with tetracycline resistance (1116,18). Doxycycline has become the tetracycline analogue
of choice for treating brucellosis because of its superior
pharmacokinetics, lipophilic ability, and bioavailability
(16). Among the antibacterial agents used to treat
brucellosis, doxycyline has shown the lowest MIC90 values
(9,11-14). In the present study, tetracycline and
ciprofloxacin shared the lowest MIC values among the
antibiotics tested. Although streptomycin is known to be
active against brucellosis (6,13,15), its disadvantages,
such as ototoxicity, nephrotoxicity, and parenteral
administration, preclude its wider use. Even though
rifampin is somewhat toxic, it has the advantage of oral
administration (19,20). In the present study none of the
isolates were resistant to rifampin, although 2 showed
intermediate sensitivity. In a previous study that assessed
the antimicrobial susceptibility of Brucellae at different
pH levels, rifampin was the only antibiotic with increased
activity in acidic environmental conditions (6). In clinical
trials, the doxycycline-rifampin combination was as
effective as the doxycycline-streptomycin combination in
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the majority of Brucella infections, excluding Brucella
spondylitis, for which streptomycin is recommended
(20). Fluoroquinolones represent candidate therapeutic
alternatives for brucellosis because of their excellent
bioavailability, intracellular penetration, and ability to
achieve optimum tissue concentrations (6,21). In vitro
studies of quinolones have demonstrated favorable
antimicrobial activity against Brucella spp. (11-13). Our
study revealed compatible results, suggesting that in vitro
ciprofloxacin was as effective as tetracycline against B.
melitensis strains. Nonetheless, fluoroquinolones have the
disadvantage of reduced activity in acidic environments
(6,16). It was also demonstrated that ciprofloxacin
monotherapy increases the probability of relapse
(22,23). There are also some studies that assessed
quinolones as components of combination regimens,
suggesting efficacy equal to classically recommended
combination schemes (24-26). Currently, published
randomized clinical trials do not support the use of
quinolone-based combinations as a first-line therapy (27).
Azithromycin is a new macrolide with good
intracellular penetration and in vitro activity against
Brucellae (28). Acidic environmental conditions also
impair the activity of macrolides (6). The present study
found favorable in vitro activity of azithromycin against
Brucella strains. Yamazhan et al. reported high MIC
values for both azithromycin and fluoroquinolones with
the agar dilution method, and proposed increased
resistance of Brucella strains to both antimicrobial agents
(14). Their finding may be explained by regional and
methodological differences. Large-scale clinical trials
involving azithromycin in human brucellosis are lacking. A
small clinical trial (29) refuted the efficacy of an
azithromycin-gentamycin combination in human
brucellosis; however, in vitro results are encouraging and
warrant further clinical study of azithromycin for Brucella
infections.
Reports from Turkey revealed that, in vitro, several
antibiotics are effective against Brucella isolates and that
the problem of resistance seems minor. Our results are
consistent with a recent study from Greece that evaluated
the antimicrobial susceptibility of 74 B. melitensis isolates
using the E test (15). Lopez-Merino et al. from Mexico
reported that in vitro antibacterial activity of quinolones
approximated that of tetracyclines, and exceeded that of
streptomycin and rifampin (30). The authors encouraged
the evaluation of these drugs in clinical trials.
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In conclusion, classically recommended therapeutics
for brucellosis show favorable in vitro antibacterial
activity profiles. Ciprofloxacin also seems to be
promising, as it had anti-Brucella activity equal to that of
tetracyclines in our study. Azithromycin is effective in
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vitro, although its in vivo efficacy remains to be
confirmed. Future large-scale, randomized, double-blind
in vivo comparison studies that assess these antibacterial
agents in various combination protocols are warranted.
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